Physician profile
Stanley R Cushing
NPI 1710985338
$906.29
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $137 · 2021: $241 · 2022: $321 · 2023: $17.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $222.07 | 2019-2021 | |
| Notal Vision, INC. | $175.86 | 2022 | |
| Eyevance Pharmaceuticals LLC | $73.41 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $57.70 | 2019-2021 | |
| Alcon Vision LLC | $50.27 | 2022-2023 | Eysuvis |
| Bausch & Lomb Americas INC. | $38.95 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Allergan, INC. | $35.90 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $34.54 | 2020-2021 | |
| Glaukos Corporation | $29.20 | 2021 | |
| Kala Pharmaceuticals, INC. | $21.56 | 2021 | |
| Aerie Pharmaceuticals, INC. | $21.27 | 2021 | |
| Thea Pharma INC. | $20.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.25 | 2022 | |
| Akorn, INC. | $19.50 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $18.81 | 2021 | |
| Coopervision INC. | $15.66 | 2022 | |
| New World Medical,INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Cushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.